Immune Thrombocytopenia Market Insights, Epidemiology, and Pipeline Insights – 2017-30

Immune Thrombocytopenia Market Insights, Epidemiology, and Pipeline Insights - 2017-30

“Immune Thrombocytopenia (ITP) Market | ITP Market”
The market size of ITP in the 7MM was found to be USD 2,527.72 million in 2017. The United States accounts for the highest market size of Immune Thrombocytopenia (ITP), in comparison to the other major markets i.e., EU5 countries, and Japan.

DelveInsight’s ‘Immune Thrombocytopenia (ITP)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The ITP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM ITP market size from 2017 to 2030. The Report also covers current ITP treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Disease Overview

Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of immune thrombocytopenia, stem from a low platelet count leading to excessive bleeding.

Click to read more.

Immune Thrombocytopenia (ITP) Epidemiology 

DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.

Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Visit to know more about the report.

Immune Thrombocytopenia (ITP) Market

The US Food and Drug Administration (FDA) has approved three Thrombopoietin receptor agonist (TPO-RA) therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). For Europe and Japan, only two TPO-RAs is approved, i.e., Nplate and Promacta. Promacta and Nplate will lose their patent in 2022 in the US, whereas, in Europe and Japan, Nplate loses the patent in 2019 and Promacta will lose patent in 2025. Due to their patent expiry, it is expected that the approval of Doptelet is likely to cover a major patient pool.

The major goal for the treatment of ITP is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels. The management of ITP varies widely and current international guidelines recommend several first- and second-line options, including some medicinal products that have not been approved in the EU for this particular condition.

Key Findings

The market size of ITP in the 7MM was found to be USD 2,527.72 million in 2017.

The United States accounts for the highest market size of Immune Thrombocytopenia (ITP), in comparison to the other major markets i.e., EU5 countries, and Japan

Among the EU5 countries, the UK had the highest market size with USD 247.89 million in 2017, while Spain had the lowest market size of ITP with USD 115.08 million in 2017.

From 2023, the market value will start declining due to the patent expiration and subsequent launch of generic/biosimilar of Nplate and Promacta.

So, till 2022 Doptelet will continue to compete with both these drugs and after the patent expiry, Doptelet will not have any competitor in the market. Doptelet has contributed USD 15.50 million of the total market size of the disease in 2019.

Request for sample pages.

Immune Thrombocytopenia (ITP) Marketed Drugs

Doptelet (Avatrombopag): Dova Pharmaceuticals

Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals

Nplate (AMG-531): Amgen


Immune Thrombocytopenia (ITP) Emerging Drugs

BT-595: Biotest

Rozanolixizumab: UCB Biopharma

Efgartigimod (ARGX-113): Argenx


Key Companies in the Immune Thrombocytopenia Market

Key pharma companies fuelling the Immune thrombocytopenia (ITP) market are Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Zenyaku Kogyo/Biogen Idec, Novartis, Bio Products Laboratory’s, Takeda Pharmaceutical Company Limited, AstraZeneca, Biotest, GC Pharma, SK Plasma, Jiangsu HengRui Medicine, Argenx, Genosco (a US-based subsidiary of Korean bio company Oscotec), Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, Protalex and others.



Table of contents

1              Key Insights

2              Executive Summary of Immune Thrombocytopenia (ITP)

3              Immune thrombocytopenia (ITP) Market Overview at a Glance

4              SWOT Analysis

5              Immune Thrombocytopenia (ITP): Disease Background and Overview

6              Immune Thrombocytopenia (ITP) Epidemiology Methodology

7              Immune Thrombocytopenia (ITP) Epidemiology and Patient Population

8              Country Wise Immune Thrombocytopenia (ITP) Epidemiology

9              Immune Thrombocytopenia (ITP) Treatment and Management

10           Immune Thrombocytopenia (ITP) Patient Journey

11           Unmet Needs in Immune Thrombocytopenia (ITP) Market

12           Key Endpoints of Immune Thrombocytopenia (ITP)

13           Immune Thrombocytopenia (ITP) Marketed Products

14           Immune Thrombocytopenia (ITP) Emerging Therapies

15           Attribute Analysis of Immune Thrombocytopenia Therapies

16           Immune Thrombocytopenia (ITP): 7MM Market Analysis

17           United States: Immune Thrombocytopenia (ITP) Market Outlook

18           EU-5 countries: Immune Thrombocytopenia (ITP) Market Outlook

19           Japan Immune Thrombocytopenia (ITP) Market Outlook

20           Access and Reimbursement Overview for Current and Future Therapies

21           Immune thrombocytopenia (ITP) Market Drivers

22           Immune thrombocytopenia (ITP) Market Barriers

23           Appendix

24           DelveInsight Capabilities

25           Disclaimer

26           About DelveInsight


About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

Browse through our vast repository

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States